About Adenylate cyclase type 1
Adenylate cyclase type 1 (ADCY1) is a protein
from Homo sapiens identified by UniProt accession
Q08828, 1119 residues long.
MolForge cross-references it against 0 known binders and
484 disease associations.
Target properties
| Protein name | Adenylate cyclase type 1 |
|---|
| UniProt accession | Q08828 |
|---|
| Gene | ADCY1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 1119 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Approved drugs hitting this target (1)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (484)
Diseases linked to this target (Open Targets).
- hearing loss, autosomal recessive · score 0.46
- deafness · score 0.36
- schizophrenia · score 0.28
- bipolar disorder · score 0.28
- response to lithium ion · score 0.28
- lung adenocarcinoma · score 0.24
- glioblastoma multiforme · score 0.22
- genetic disorder · score 0.19
- cutaneous melanoma · score 0.17
- head and neck squamous cell carcinoma · score 0.12
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q08828-F1 | alphafold | PREDICTED | 77.42 | — |
Amino-acid sequence (1119 residues)
MAGAPRGGGG GGGGAGEPGG AERAAGTSRR RGLRACDEEF ACPELEALFR GYTLRLEQAA TLKALAVLSL LAGALALAEL LGAPGPAPGL AKGSHPVHCV LFLALLVVTN VRSLQVPQLQ QVGQLALLFS LTFALLCCPF ALGGPARGSA GAAGGPATAE QGVWQLLLVT FVSYALLPVR SLLAIGFGLV VAASHLLVTA TLVPAKRPRL WRTLGANALL FVGVNMYGVF VRILTERSQR KAFLQARSCI EDRLRLEDEN EKQERLLMSL LPRNVAMEMK EDFLKPPERI FHKIYIQRHD NVSILFADIV GFTGLASQCT AQELVKLLNE LFGKFDELAT ENHCRRIKIL GDCYYCVSGL TQPKTDHAHC CVEMGLDMID TITSVAEATE VDLNMRVGLH TGRVLCGVLG LRKWQYDVWS NDVTLANVME AAGLPGKVHI TKTTLACLNG DYEVEPGYGH ERNSFLKTHN IETFFIVPSH RRKIFPGLIL SDIKPAKRMK FKTVCYLLVQ LMHCRKMFKA EIPFSNVMTC EDDDKRRALR TASEKLRNRS SFSTNVVYTT PGTRVNRYIS RLLEARQTEL EMADLNFFTL KYKHVEREQK YHQLQDEYFT SAVVLTLILA ALFGLVYLLI FPQSVVVLLL LVFCICFLVA CVLYLHITRV QCFPGCLTIQ IRTVLCIFIV VLIYSVAQGC VVGCLPWAWS SKPNSSLVVL SSGGQRTALP TLPCESTHHA LLCCLVGTLP LAIFFRVSSL PKMILLSGLT TSYILVLELS GYTRTGGGAV SGRSYEPIVA ILLFSCALAL HARQVDIRLR LDYLWAAQAE EEREDMEKVK LDNRRILFNL LPAHVAQHFL MSNPRNMDLY YQSYSQVGVM FASIPNFNDF YIELDGNNMG VECLRLLNEI IADFDELMEK DFYKDIEKIK TIGSTYMAAV GLAPTSGTKA KKSISSHLST LADFAIEMFD VLDEINYQSY NDFVLRVGIN VGPVVAGVIG ARRPQYDIWG NTVNVASRMD STGVQGRIQV TEEVHRLLRR CPYHFVCRGK VSVKGKGEML TYFLEGRTDG NGSQIRSLGL DRKMCPFGRA GLQGRRPPVC PMPGVSVRAG LPPHSPGQYL PSAAAGKEA
Explore Adenylate cyclase type 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets